The road from discovery to clinic: Adiponectin as a biomarker of metabolic status

C. M. Kusminski; P. E. Scherer

doi:10.1038/clpt.2009.155

The road from discovery to clinic: Adiponectin as a biomarker of metabolic status

C. M. Kusminski, P. E. Scherer

Research output: Contribution to journal › Comment/debate › peer-review

46 Scopus citations

Abstract

Biomarkers are globally used to monitor clinical responses to therapeutic and lifestyle interventions. The adipocyte-derived hormone adiponectin is recognized as a promising new biomarker owing to its many associations with components of the metabolic syndrome. The study described by Wagner and colleagues in this issue offers a first example of how a large-scale effort in the context of a cross-company collaborative study in the pharmaceutical industry can offer a powerful tool for the further validation of a new biomarker in the context of pharmacological intervention with peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists.

Original language	English (US)
Pages (from-to)	592-595
Number of pages	4
Journal	Clinical pharmacology and therapeutics
Volume	86
Issue number	6
DOIs	https://doi.org/10.1038/clpt.2009.155
State	Published - 2009

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1038/clpt.2009.155

Cite this

@article{22e9ee34d3fa40d5954580337c4d84c8,

title = "The road from discovery to clinic: Adiponectin as a biomarker of metabolic status",

abstract = "Biomarkers are globally used to monitor clinical responses to therapeutic and lifestyle interventions. The adipocyte-derived hormone adiponectin is recognized as a promising new biomarker owing to its many associations with components of the metabolic syndrome. The study described by Wagner and colleagues in this issue offers a first example of how a large-scale effort in the context of a cross-company collaborative study in the pharmaceutical industry can offer a powerful tool for the further validation of a new biomarker in the context of pharmacological intervention with peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists.",

author = "Kusminski, {C. M.} and Scherer, {P. E.}",

year = "2009",

doi = "10.1038/clpt.2009.155",

language = "English (US)",

volume = "86",

pages = "592--595",

journal = "Clinical pharmacology and therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - The road from discovery to clinic

T2 - Adiponectin as a biomarker of metabolic status

AU - Kusminski, C. M.

AU - Scherer, P. E.

PY - 2009

Y1 - 2009

N2 - Biomarkers are globally used to monitor clinical responses to therapeutic and lifestyle interventions. The adipocyte-derived hormone adiponectin is recognized as a promising new biomarker owing to its many associations with components of the metabolic syndrome. The study described by Wagner and colleagues in this issue offers a first example of how a large-scale effort in the context of a cross-company collaborative study in the pharmaceutical industry can offer a powerful tool for the further validation of a new biomarker in the context of pharmacological intervention with peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists.

AB - Biomarkers are globally used to monitor clinical responses to therapeutic and lifestyle interventions. The adipocyte-derived hormone adiponectin is recognized as a promising new biomarker owing to its many associations with components of the metabolic syndrome. The study described by Wagner and colleagues in this issue offers a first example of how a large-scale effort in the context of a cross-company collaborative study in the pharmaceutical industry can offer a powerful tool for the further validation of a new biomarker in the context of pharmacological intervention with peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists.

UR - http://www.scopus.com/inward/record.url?scp=70450134177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450134177&partnerID=8YFLogxK

U2 - 10.1038/clpt.2009.155

DO - 10.1038/clpt.2009.155

M3 - Comment/debate

C2 - 19915603

AN - SCOPUS:70450134177

SN - 0009-9236

VL - 86

SP - 592

EP - 595

JO - Clinical pharmacology and therapeutics

JF - Clinical pharmacology and therapeutics

IS - 6

ER -

The road from discovery to clinic: Adiponectin as a biomarker of metabolic status

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this